

Role of Florbetapir Scanning in Diagnosing
Cognitive Disorders among First 20
Consecutive Patients Imaged at Mount Sinai
Medical Center
from June 1-December 1, 2012

Sam Gandy MD PhD
Mount Sinai Chair in Alzheimer's Disease
Research
Director, Center for Cognitive Health and
NFL Neurological Program

Effie Mitsis PhD
Assistant Professor of Psychiatry
Mount Sinai School of Medicine

Disclosures

<\$10,000/yr

DSMB member, AAC-001 (A β vaccine) trial
Janssen Alzheimer Immunotherapy Alliance (J&J,
Pfizer)

SAB member, blood biomarker discovery
Diagenic

SAB member, clinical trial in Down Syndrome
Balance Therapeutics

>\$100,000/yr (research costs, not personal
income)

Grantee, Amicus Therapeutics, GM1 modulation

Florbetapir had an obvious impact on diagnosis in 9 of first 20 consecutive patients imaged at a tertiary, urban Alzheimer Center

- “FTD-like” clinical picture (PPA or predominant behavioral disorder) but over age 70 yrs
- Rapidly progressive dementias
- Exclusion of AD in clinical CTE
- Exclusion of AD in depression + MCI
- Exclusion of AD in static MCI

In some of the 11 other cases, patient preference over LP and/or physician confidence in imaging over CSF played a role.

- Patients 1-10 (florbetapir status)

- 80, M, static memory disorder, *APOE4+* (negative)
- 70, F, PPA, (positive)
- 60, F, PPA (negative)
- 67, F, PPA (negative)
- 81, M, Parkinson's with dementia (positive)
- 79, F, worried well (negative)
- 78, M, MCI (positive)
- 75, F, Parkinson's with depression (negative)
- 74, M, behavioral disorder (negative)
- 89, F, MCI, positive

- Patients 11-20 (florbetapir status)

- 83, M, MCI, positive
- 77, M, MCI, positive
- 77, F, depression & MCI, negative
- 71, F, AD, positive
- 72, M, AD, positive
- 71, M, CTE vs AD (experts disagreed), negative
- 77, M, AD, positive
- 65, F, AD, positive
- 50, M, limbic encephalitis vs AD, positive
- 59, M, dementia w TBI, focally positive at impact

Florbetapir had an obvious impact on diagnosis in 9 of first 20 consecutive patients imaged at a tertiary, urban Alzheimer Center

- “FTD-like” clinical picture (PPA or predominant behavioral disorder) but over age 70 yrs
- Rapidly progressive dementias
- Exclusion of AD in clinical CTE
- Exclusion of AD in depression + MCI
- Exclusion of AD in static MCI

In some of the 11 other cases, patient preference over LP and/or physician confidence in imaging over CSF played a role.